Goldman Sachs Boosts Royalty Pharma Target to $51, Citing Strong Growth Trajectory Through 2026

In a significant vote of confidence for the biopharmaceutical royalty sector, Goldman Sachs has elevated its price target for Royalty Pharma plc (NASDAQ: RPRX) to $51, up from $45, while reaffirming its Buy rating. The move comes on the heels of the company's stronger-than-anticipated fourth-quarter performance and a 2026 growth outlook that has surpassed market expectations.

The investment bank pointed to Royalty Pharma's portfolio receipts and forward guidance as key drivers, suggesting a year-over-year royalty growth of 3% to 8%. Analysts emphasized the firm's positioning for sustained top-line growth above 10%, bolstered by synthetic royalty performance, continued commercial success of its partnered therapies, and a favorable royalty financing environment. With approximately $3.5 billion in available capital, Royalty Pharma is well-equipped to maintain an active deal-making pace.

For 2026, management provided portfolio receipt guidance of $3.275 billion to $3.425 billion, based on the current portfolio and excluding future acquisitions. The company anticipates a reduction in milestone payments and projects operating costs to decline as a percentage of receipts. A 7% dividend increase for 2026 was also announced, aligning with the company's commitment to returning capital to shareholders alongside strategic investments.

Market Pulse: Analyst & Investor Reactions

"This isn't just a quarterly beat; it's a validation of their entire business model," commented David Chen, a portfolio manager at Horizon Capital. "The raised guidance and financial capacity signal they're not just collecting royalties, but actively shaping a high-growth pipeline."

Offering a more tempered perspective, Dr. Anya Sharma, a biotech analyst at Veritas Insights, noted, "The long-term growth thesis is compelling, but the decline in milestone payments for 2026 is a reminder that this revenue stream can be lumpy. Execution on new deals is critical to meet those elevated targets."

A sharper critique came from Marcus Reed, an independent investor and frequent financial commentator. "Let's not get carried away," he stated. "This is a financial engineering play dressed up as biotech innovation. Their 'growth' is heavily reliant on continuously raising and deploying massive capital. When the financing music stops, the multiple will contract."

Founded in 1996 and headquartered in New York City, Royalty Pharma is the world's largest buyer of biopharmaceutical royalties, acting as a key funding partner for innovators from academic institutions to global pharmaceutical giants.